The original confidentiality arrangement, established in 2007, has been extended after all parties found it to be a useful tool in regulatory cooperation. It allows exchange of:
- advance drafts of legislation and regulatory guidance documents;
- scientific advice on medicine development;
- assessments of applications for marketing authorisations;
- information about the safety of marketed medicines.
As part of these arrangements, Japan has also seconded a representative to the European Medicines Agency's offices in London since late 2009.